FDA Orange Book
Generic for Giapreza
Giapreza contains angiotensin ii acetate. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Giapreza is angiotensin ii acetate. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AP. Generics match 1 of the 3 Giapreza products the Orange Book lists.
Run it in Rivvi
Map Giapreza and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Giapreza products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, intravenous | EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) | Marketed (Rx) | None | 0 | None |
| solution, intravenous | EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) | Marketed (Rx) | AP | 1 | AP |
| solution, intravenous | EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) | Discontinued | None | 0 | None |
NDA 209360, held by LA JOLLA PHARMA LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic angiotensin ii acetate
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| GLAND PHARMA LTD | 216966 | AP (A-rated, therapeutically equivalent) | June 3, 2025 | EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) |
Giapreza patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 10500247 | December 16, 2029 | Method of use | U-2681 | 209360 |
| 10500247 | December 16, 2029 | Method of use | U-2680 | 209360 |
| 10548943 | December 16, 2029 | Method of use | U-2740 | 209360 |
| 10548943 | December 16, 2029 | Method of use | U-2739 | 209360 |
| 10335451 | December 16, 2029 | Method of use | U-2581 | 209360 |
| 9867863 | December 16, 2029 | Method of use | U-2231 | 209360 |
| 9572856 | July 18, 2031 | Method of use | U-2221 | 209360 |
| 11559559 | December 18, 2034 | Method of use | U-3514 | 209360 |
| 10493124 | December 18, 2034 | Method of use | U-2679 | 209360 |
| 11096983 | December 18, 2034 | Method of use | U-3212 | 209360 |
| 11096983 | December 18, 2034 | Method of use | U-3211 | 209360 |
| 10028995 | December 18, 2034 | Method of use | U-2338 | 209360 |
| 9220745 | December 18, 2034 | Method of use | U-2217 | 209360 |
| 9220745 | December 18, 2034 | Method of use | U-2218 | 209360 |
| 11219662 | January 6, 2037 | Method of use | U-3262 | 209360 |
Giapreza NDC codes
Questions
Is there a generic for Giapreza?
Yes. The generic name for Giapreza is angiotensin ii acetate. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AP. Generics match 1 of the 3 Giapreza products the Orange Book lists.
What is the generic name for Giapreza?
The active ingredient in Giapreza is angiotensin ii acetate, per the FDA Orange Book.
When does the Giapreza patent expire?
The last patent listed for Giapreza in the Orange Book expires January 6, 2037. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.